GAfPA Blog

The GAfPA Patient Advocacy Blog

Are Regulators Too Hasty in Approving Cancer Drugs?

The British Medical Journal ignited debate earlier last month when it announced that about half of cancer drugs approved by the European Medicines Agency don’t improve survival or quality of life.  The claim begs several complex question: How can regulators evaluate drugs both quickly and effectively?  And whose values should determine access to drugs for … Continued

“Fast Facts” on Pharmacovigilance Tackles Drug Safety Issues

Drug safety issues have caused more than 200,000 patient deaths in the EU. And one in three U.S. drugs may have safety issues, explains a new “Fast Facts” from the Global Alliance for Patient Access.   The paper explores how countries track and trace prescription drug side effects – and why advanced medicine demands a stronger … Continued

BLOG: GAfPA Examines How Improving Drug Donations Can Boost Patient Access

Reposted from the Institute for Patient Access   International prescription drug donation programs make a difference, explains a new white paper from the Global Alliance for Patient Access.  But they could work even better. In “The Role of Drug Donations in Expanding Access to Medicines,” author Neeraj Mistry, MD, MPH, explains that, “Millions of low-income … Continued

VÍDEO: Entender El Cambio O Switch No Médico

Los pacientes con condiciones médicas crónicas o graves a veces deben trabajar con los médicos durante meses para identificar un medicamento que sea eficaz para ellos. Pero como lo explica este video, los pacientes pueden descubrir que este proceso de prueba y error fue en vano. A través del cambio o switch no médico, las … Continued

Munich 2017

The Global Alliance for Patient Access (GAfPA) and the European Federation of Crohn’s and Colitis Associations (EFCCA) came together to hold a Biologics and Biosimilars Patient Access and Advocacy Workshop in Munich, Germany on May 4-5, 2017. The 17 attendees from 13 different countries represented specialities from across rheumatology, gastroenterology and neurology, including several members … Continued

Advocates Strategize on Pain Care Policy at GAfPA’s Malta Workshop

Advocates Strategize on Pain Care Policy at GAfPA’s Malta Workshop   Young King David beat the biblical giant Goliath, as advocates at a Global Alliance for Patient Access workshop in Malta were recently reminded.  In the same way, a small group of committed advocates can rival much larger, more powerful interest groups – impacting policy … Continued

EU Group Calls for Greater Transparency in Labelling Biosimilars

  EU regulators who want to encourage understanding and acceptance of biosimilar medicines might consider improving the drugs’ labels.  So says the stakeholders group EuropaBio, which has issued recommendations for enhancing transparency in the literature that accompanies a biosimilar. Known as the summary of product characteristics, this documentation is required by the European Commission to … Continued

Access Issues Loom Large at Munich Workshop on Biologics and Biosimilars

When should patients switch from one medicine to another for non-medical reasons? How can pharmacovigilance processes successfully monitor patients’ reactions to a medicine? And, perhaps most importantly, how do we ensure that patients are informed participants in decisions about their medication?   These questions and others framed a May 4-5 advocacy workshop in Munich, hosted … Continued